nodes	percent_of_prediction	percent_of_DWPC	metapath
Fluoxetine—ALB—lung cancer	0.116	0.512	CbGaD
Fluoxetine—ABCB1—lung cancer	0.11	0.488	CbGaD
Fluoxetine—ORM1—Gefitinib—lung cancer	0.0511	0.102	CbGbCtD
Fluoxetine—ORM1—Erlotinib—lung cancer	0.0302	0.0606	CbGbCtD
Fluoxetine—ALB—Gefitinib—lung cancer	0.0215	0.0431	CbGbCtD
Fluoxetine—CYP3A5—Gefitinib—lung cancer	0.0173	0.0347	CbGbCtD
Fluoxetine—CYP3A5—Teniposide—lung cancer	0.0168	0.0336	CbGbCtD
Fluoxetine—CYP2C19—Gefitinib—lung cancer	0.0139	0.028	CbGbCtD
Fluoxetine—CYP2C19—Teniposide—lung cancer	0.0135	0.0271	CbGbCtD
Fluoxetine—ALB—Erlotinib—lung cancer	0.0127	0.0255	CbGbCtD
Fluoxetine—ABCB1—Topotecan—lung cancer	0.0123	0.0247	CbGbCtD
Fluoxetine—CYP2B6—Irinotecan—lung cancer	0.0117	0.0235	CbGbCtD
Fluoxetine—CYP2C9—Gefitinib—lung cancer	0.0116	0.0232	CbGbCtD
Fluoxetine—ALB—Irinotecan—lung cancer	0.0115	0.023	CbGbCtD
Fluoxetine—ABCB1—Gefitinib—lung cancer	0.0112	0.0226	CbGbCtD
Fluoxetine—CYP2C9—Teniposide—lung cancer	0.0112	0.0225	CbGbCtD
Fluoxetine—CYP2D6—Gefitinib—lung cancer	0.0106	0.0213	CbGbCtD
Fluoxetine—CYP3A5—Crizotinib—lung cancer	0.0106	0.0212	CbGbCtD
Fluoxetine—CYP3A5—Erlotinib—lung cancer	0.0102	0.0205	CbGbCtD
Fluoxetine—CYP2B6—Cisplatin—lung cancer	0.00955	0.0192	CbGbCtD
Fluoxetine—CYP3A5—Paclitaxel—lung cancer	0.00935	0.0188	CbGbCtD
Fluoxetine—CYP3A5—Irinotecan—lung cancer	0.00923	0.0185	CbGbCtD
Fluoxetine—ABCB1—Vinorelbine—lung cancer	0.00866	0.0174	CbGbCtD
Fluoxetine—CYP2D6—Vinorelbine—lung cancer	0.00816	0.0164	CbGbCtD
Fluoxetine—CYP1A2—Erlotinib—lung cancer	0.0076	0.0153	CbGbCtD
Fluoxetine—CYP3A5—Etoposide—lung cancer	0.00739	0.0148	CbGbCtD
Fluoxetine—CYP3A4—Topotecan—lung cancer	0.00737	0.0148	CbGbCtD
Fluoxetine—ABCB1—Crizotinib—lung cancer	0.00689	0.0138	CbGbCtD
Fluoxetine—CYP3A5—Docetaxel—lung cancer	0.00676	0.0136	CbGbCtD
Fluoxetine—CYP3A4—Gefitinib—lung cancer	0.00674	0.0135	CbGbCtD
Fluoxetine—ABCB1—Gemcitabine—lung cancer	0.00674	0.0135	CbGbCtD
Fluoxetine—ABCB1—Erlotinib—lung cancer	0.00665	0.0133	CbGbCtD
Fluoxetine—CYP3A4—Teniposide—lung cancer	0.00653	0.0131	CbGbCtD
Fluoxetine—CYP2B6—Doxorubicin—lung cancer	0.0064	0.0128	CbGbCtD
Fluoxetine—CYP2C9—Paclitaxel—lung cancer	0.00627	0.0126	CbGbCtD
Fluoxetine—CYP2D6—Erlotinib—lung cancer	0.00627	0.0126	CbGbCtD
Fluoxetine—ABCB1—Paclitaxel—lung cancer	0.00609	0.0122	CbGbCtD
Fluoxetine—ALB—Methotrexate—lung cancer	0.00608	0.0122	CbGbCtD
Fluoxetine—ABCB1—Irinotecan—lung cancer	0.00601	0.012	CbGbCtD
Fluoxetine—CYP1A2—Etoposide—lung cancer	0.0055	0.011	CbGbCtD
Fluoxetine—HTR2A—phrenic nerve—lung cancer	0.00548	0.276	CbGeAlD
Fluoxetine—ABCB1—Vinblastine—lung cancer	0.00534	0.0107	CbGbCtD
Fluoxetine—CYP3A4—Vinorelbine—lung cancer	0.00519	0.0104	CbGbCtD
Fluoxetine—CYP2C9—Cisplatin—lung cancer	0.00504	0.0101	CbGbCtD
Fluoxetine—CYP2D6—Vinblastine—lung cancer	0.00503	0.0101	CbGbCtD
Fluoxetine—ABCB1—Cisplatin—lung cancer	0.0049	0.00982	CbGbCtD
Fluoxetine—ABCB1—Etoposide—lung cancer	0.00481	0.00965	CbGbCtD
Fluoxetine—ABCB1—Docetaxel—lung cancer	0.0044	0.00883	CbGbCtD
Fluoxetine—CYP3A4—Crizotinib—lung cancer	0.00413	0.00828	CbGbCtD
Fluoxetine—CYP3A4—Erlotinib—lung cancer	0.00398	0.00799	CbGbCtD
Fluoxetine—CYP3A4—Paclitaxel—lung cancer	0.00365	0.00731	CbGbCtD
Fluoxetine—CYP3A4—Irinotecan—lung cancer	0.0036	0.00722	CbGbCtD
Fluoxetine—ABCB1—Doxorubicin—lung cancer	0.00328	0.00658	CbGbCtD
Fluoxetine—CYP3A4—Vinblastine—lung cancer	0.0032	0.00642	CbGbCtD
Fluoxetine—ABCB1—Methotrexate—lung cancer	0.00318	0.00637	CbGbCtD
Fluoxetine—CYP2D6—Doxorubicin—lung cancer	0.00309	0.0062	CbGbCtD
Fluoxetine—CYP3A4—Etoposide—lung cancer	0.00288	0.00578	CbGbCtD
Fluoxetine—CYP3A4—Docetaxel—lung cancer	0.00264	0.00529	CbGbCtD
Fluoxetine—HTR2A—pulmonary artery—lung cancer	0.00199	0.1	CbGeAlD
Fluoxetine—CYP3A4—Doxorubicin—lung cancer	0.00197	0.00394	CbGbCtD
Fluoxetine—ALB—mammary gland—lung cancer	0.000977	0.0491	CbGeAlD
Fluoxetine—SIGMAR1—mammary gland—lung cancer	0.000943	0.0474	CbGeAlD
Fluoxetine—SLC6A4—respiratory system—lung cancer	0.000633	0.0318	CbGeAlD
Fluoxetine—CYP2C9—mammary gland—lung cancer	0.00061	0.0307	CbGeAlD
Fluoxetine—SLC6A2—respiratory system—lung cancer	0.000557	0.028	CbGeAlD
Fluoxetine—SIGMAR1—bronchus—lung cancer	0.000517	0.026	CbGeAlD
Fluoxetine—SIGMAR1—trachea—lung cancer	0.000464	0.0233	CbGeAlD
Fluoxetine—SIGMAR1—cardiac atrium—lung cancer	0.000436	0.0219	CbGeAlD
Fluoxetine—ORM1—bone marrow—lung cancer	0.000435	0.0219	CbGeAlD
Fluoxetine—CYP1A2—respiratory system—lung cancer	0.000428	0.0215	CbGeAlD
Fluoxetine—CYP3A5—respiratory system—lung cancer	0.000413	0.0208	CbGeAlD
Fluoxetine—CYP2B6—respiratory system—lung cancer	0.00041	0.0206	CbGeAlD
Fluoxetine—ORM1—lung—lung cancer	0.000394	0.0198	CbGeAlD
Fluoxetine—SIGMAR1—bone marrow—lung cancer	0.000368	0.0185	CbGeAlD
Fluoxetine—CYP2B6—bronchus—lung cancer	0.000338	0.017	CbGeAlD
Fluoxetine—SLC6A4—lung—lung cancer	0.000336	0.0169	CbGeAlD
Fluoxetine—HTR2A—respiratory system—lung cancer	0.000335	0.0168	CbGeAlD
Fluoxetine—SIGMAR1—lung—lung cancer	0.000334	0.0168	CbGeAlD
Fluoxetine—SLC6A2—lung—lung cancer	0.000296	0.0149	CbGeAlD
Fluoxetine—HTR2A—epithelium—lung cancer	0.00028	0.0141	CbGeAlD
Fluoxetine—ORM1—lymph node—lung cancer	0.00027	0.0136	CbGeAlD
Fluoxetine—HTR2A—trachea—lung cancer	0.000247	0.0124	CbGeAlD
Fluoxetine—ALB—lymph node—lung cancer	0.000236	0.0119	CbGeAlD
Fluoxetine—SIGMAR1—lymph node—lung cancer	0.000228	0.0115	CbGeAlD
Fluoxetine—CYP1A2—lung—lung cancer	0.000227	0.0114	CbGeAlD
Fluoxetine—ABCB1—respiratory system—lung cancer	0.000219	0.011	CbGeAlD
Fluoxetine—CYP3A5—lung—lung cancer	0.000219	0.011	CbGeAlD
Fluoxetine—CYP2B6—lung—lung cancer	0.000218	0.011	CbGeAlD
Fluoxetine—SLC6A2—lymph node—lung cancer	0.000202	0.0102	CbGeAlD
Fluoxetine—ABCB1—epithelium—lung cancer	0.000183	0.00922	CbGeAlD
Fluoxetine—HTR2A—lung—lung cancer	0.000178	0.00894	CbGeAlD
Fluoxetine—ABCB1—trachea—lung cancer	0.000162	0.00815	CbGeAlD
Fluoxetine—ABCB1—bone marrow—lung cancer	0.000129	0.00646	CbGeAlD
Fluoxetine—ABCB1—lung—lung cancer	0.000116	0.00586	CbGeAlD
Fluoxetine—ABCB1—lymph node—lung cancer	7.97e-05	0.00401	CbGeAlD
Fluoxetine—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—lung cancer	3.79e-05	0.000211	CcSEcCtD
Fluoxetine—Pain—Etoposide—lung cancer	3.77e-05	0.00021	CcSEcCtD
Fluoxetine—Constipation—Etoposide—lung cancer	3.77e-05	0.00021	CcSEcCtD
Fluoxetine—Dysuria—Doxorubicin—lung cancer	3.76e-05	0.000209	CcSEcCtD
Fluoxetine—Decreased appetite—Paclitaxel—lung cancer	3.75e-05	0.000209	CcSEcCtD
Fluoxetine—Dry mouth—Docetaxel—lung cancer	3.73e-05	0.000208	CcSEcCtD
Fluoxetine—Upper respiratory tract infection—Doxorubicin—lung cancer	3.73e-05	0.000208	CcSEcCtD
Fluoxetine—Haemoglobin—Methotrexate—lung cancer	3.73e-05	0.000208	CcSEcCtD
Fluoxetine—Gastrointestinal disorder—Paclitaxel—lung cancer	3.73e-05	0.000208	CcSEcCtD
Fluoxetine—Fatigue—Paclitaxel—lung cancer	3.72e-05	0.000208	CcSEcCtD
Fluoxetine—Hepatitis—Methotrexate—lung cancer	3.71e-05	0.000207	CcSEcCtD
Fluoxetine—Haemorrhage—Methotrexate—lung cancer	3.71e-05	0.000207	CcSEcCtD
Fluoxetine—Pollakiuria—Doxorubicin—lung cancer	3.71e-05	0.000207	CcSEcCtD
Fluoxetine—Asthenia—Gemcitabine—lung cancer	3.7e-05	0.000206	CcSEcCtD
Fluoxetine—Pain—Paclitaxel—lung cancer	3.69e-05	0.000206	CcSEcCtD
Fluoxetine—Constipation—Paclitaxel—lung cancer	3.69e-05	0.000206	CcSEcCtD
Fluoxetine—Confusional state—Docetaxel—lung cancer	3.69e-05	0.000206	CcSEcCtD
Fluoxetine—Pharyngitis—Methotrexate—lung cancer	3.69e-05	0.000205	CcSEcCtD
Fluoxetine—Photosensitivity reaction—Doxorubicin—lung cancer	3.67e-05	0.000204	CcSEcCtD
Fluoxetine—Anaphylactic shock—Docetaxel—lung cancer	3.66e-05	0.000204	CcSEcCtD
Fluoxetine—Weight increased—Doxorubicin—lung cancer	3.66e-05	0.000204	CcSEcCtD
Fluoxetine—Pruritus—Gemcitabine—lung cancer	3.65e-05	0.000203	CcSEcCtD
Fluoxetine—Infection—Docetaxel—lung cancer	3.64e-05	0.000203	CcSEcCtD
Fluoxetine—Weight decreased—Doxorubicin—lung cancer	3.63e-05	0.000203	CcSEcCtD
Fluoxetine—Feeling abnormal—Etoposide—lung cancer	3.63e-05	0.000202	CcSEcCtD
Fluoxetine—Hyperglycaemia—Doxorubicin—lung cancer	3.62e-05	0.000202	CcSEcCtD
Fluoxetine—Diarrhoea—Irinotecan—lung cancer	3.62e-05	0.000202	CcSEcCtD
Fluoxetine—Pneumonia—Doxorubicin—lung cancer	3.6e-05	0.000201	CcSEcCtD
Fluoxetine—Gastrointestinal pain—Etoposide—lung cancer	3.6e-05	0.000201	CcSEcCtD
Fluoxetine—Shock—Docetaxel—lung cancer	3.6e-05	0.000201	CcSEcCtD
Fluoxetine—Thrombocytopenia—Docetaxel—lung cancer	3.58e-05	0.0002	CcSEcCtD
Fluoxetine—Drowsiness—Doxorubicin—lung cancer	3.58e-05	0.0002	CcSEcCtD
Fluoxetine—Visual impairment—Methotrexate—lung cancer	3.58e-05	0.0002	CcSEcCtD
Fluoxetine—Tachycardia—Docetaxel—lung cancer	3.57e-05	0.000199	CcSEcCtD
Fluoxetine—Feeling abnormal—Paclitaxel—lung cancer	3.56e-05	0.000198	CcSEcCtD
Fluoxetine—Skin disorder—Docetaxel—lung cancer	3.56e-05	0.000198	CcSEcCtD
Fluoxetine—Stevens-Johnson syndrome—Doxorubicin—lung cancer	3.55e-05	0.000198	CcSEcCtD
Fluoxetine—Hypersensitivity—Cisplatin—lung cancer	3.54e-05	0.000197	CcSEcCtD
Fluoxetine—Gastrointestinal pain—Paclitaxel—lung cancer	3.53e-05	0.000197	CcSEcCtD
Fluoxetine—Diarrhoea—Gemcitabine—lung cancer	3.53e-05	0.000197	CcSEcCtD
Fluoxetine—Renal failure—Doxorubicin—lung cancer	3.52e-05	0.000196	CcSEcCtD
Fluoxetine—Erythema multiforme—Methotrexate—lung cancer	3.51e-05	0.000196	CcSEcCtD
Fluoxetine—Neuropathy peripheral—Doxorubicin—lung cancer	3.51e-05	0.000196	CcSEcCtD
Fluoxetine—Dizziness—Irinotecan—lung cancer	3.5e-05	0.000195	CcSEcCtD
Fluoxetine—Urticaria—Etoposide—lung cancer	3.5e-05	0.000195	CcSEcCtD
Fluoxetine—Stomatitis—Doxorubicin—lung cancer	3.49e-05	0.000195	CcSEcCtD
Fluoxetine—Jaundice—Doxorubicin—lung cancer	3.49e-05	0.000195	CcSEcCtD
Fluoxetine—Anorexia—Docetaxel—lung cancer	3.49e-05	0.000195	CcSEcCtD
Fluoxetine—Abdominal pain—Etoposide—lung cancer	3.48e-05	0.000194	CcSEcCtD
Fluoxetine—Body temperature increased—Etoposide—lung cancer	3.48e-05	0.000194	CcSEcCtD
Fluoxetine—Conjunctivitis—Doxorubicin—lung cancer	3.48e-05	0.000194	CcSEcCtD
Fluoxetine—Urinary tract infection—Doxorubicin—lung cancer	3.48e-05	0.000194	CcSEcCtD
Fluoxetine—Tinnitus—Methotrexate—lung cancer	3.46e-05	0.000193	CcSEcCtD
Fluoxetine—Asthenia—Cisplatin—lung cancer	3.45e-05	0.000192	CcSEcCtD
Fluoxetine—Sweating—Doxorubicin—lung cancer	3.43e-05	0.000191	CcSEcCtD
Fluoxetine—Urticaria—Paclitaxel—lung cancer	3.43e-05	0.000191	CcSEcCtD
Fluoxetine—Hypotension—Docetaxel—lung cancer	3.42e-05	0.000191	CcSEcCtD
Fluoxetine—Haematuria—Doxorubicin—lung cancer	3.42e-05	0.00019	CcSEcCtD
Fluoxetine—Abdominal pain—Paclitaxel—lung cancer	3.41e-05	0.00019	CcSEcCtD
Fluoxetine—Body temperature increased—Paclitaxel—lung cancer	3.41e-05	0.00019	CcSEcCtD
Fluoxetine—Epistaxis—Doxorubicin—lung cancer	3.38e-05	0.000188	CcSEcCtD
Fluoxetine—Vomiting—Irinotecan—lung cancer	3.37e-05	0.000188	CcSEcCtD
Fluoxetine—Sinusitis—Doxorubicin—lung cancer	3.36e-05	0.000187	CcSEcCtD
Fluoxetine—Rash—Irinotecan—lung cancer	3.34e-05	0.000186	CcSEcCtD
Fluoxetine—Dermatitis—Irinotecan—lung cancer	3.34e-05	0.000186	CcSEcCtD
Fluoxetine—Musculoskeletal discomfort—Docetaxel—lung cancer	3.33e-05	0.000186	CcSEcCtD
Fluoxetine—Chills—Methotrexate—lung cancer	3.33e-05	0.000186	CcSEcCtD
Fluoxetine—Headache—Irinotecan—lung cancer	3.32e-05	0.000185	CcSEcCtD
Fluoxetine—Insomnia—Docetaxel—lung cancer	3.31e-05	0.000185	CcSEcCtD
Fluoxetine—Diarrhoea—Cisplatin—lung cancer	3.29e-05	0.000183	CcSEcCtD
Fluoxetine—Paraesthesia—Docetaxel—lung cancer	3.29e-05	0.000183	CcSEcCtD
Fluoxetine—Alopecia—Methotrexate—lung cancer	3.28e-05	0.000183	CcSEcCtD
Fluoxetine—Vomiting—Gemcitabine—lung cancer	3.28e-05	0.000183	CcSEcCtD
Fluoxetine—Bradycardia—Doxorubicin—lung cancer	3.27e-05	0.000183	CcSEcCtD
Fluoxetine—Dyspnoea—Docetaxel—lung cancer	3.26e-05	0.000182	CcSEcCtD
Fluoxetine—Somnolence—Docetaxel—lung cancer	3.25e-05	0.000181	CcSEcCtD
Fluoxetine—Mental disorder—Methotrexate—lung cancer	3.25e-05	0.000181	CcSEcCtD
Fluoxetine—Rash—Gemcitabine—lung cancer	3.25e-05	0.000181	CcSEcCtD
Fluoxetine—Dermatitis—Gemcitabine—lung cancer	3.25e-05	0.000181	CcSEcCtD
Fluoxetine—Hypersensitivity—Etoposide—lung cancer	3.24e-05	0.000181	CcSEcCtD
Fluoxetine—Malnutrition—Methotrexate—lung cancer	3.23e-05	0.00018	CcSEcCtD
Fluoxetine—Haemoglobin—Doxorubicin—lung cancer	3.23e-05	0.00018	CcSEcCtD
Fluoxetine—Headache—Gemcitabine—lung cancer	3.23e-05	0.00018	CcSEcCtD
Fluoxetine—Rhinitis—Doxorubicin—lung cancer	3.22e-05	0.00018	CcSEcCtD
Fluoxetine—Dyspepsia—Docetaxel—lung cancer	3.22e-05	0.00018	CcSEcCtD
Fluoxetine—Haemorrhage—Doxorubicin—lung cancer	3.22e-05	0.000179	CcSEcCtD
Fluoxetine—Hepatitis—Doxorubicin—lung cancer	3.22e-05	0.000179	CcSEcCtD
Fluoxetine—Hypoaesthesia—Doxorubicin—lung cancer	3.2e-05	0.000178	CcSEcCtD
Fluoxetine—Pharyngitis—Doxorubicin—lung cancer	3.19e-05	0.000178	CcSEcCtD
Fluoxetine—Decreased appetite—Docetaxel—lung cancer	3.18e-05	0.000177	CcSEcCtD
Fluoxetine—Hypersensitivity—Paclitaxel—lung cancer	3.18e-05	0.000177	CcSEcCtD
Fluoxetine—Oedema peripheral—Doxorubicin—lung cancer	3.17e-05	0.000177	CcSEcCtD
Fluoxetine—Dysgeusia—Methotrexate—lung cancer	3.17e-05	0.000176	CcSEcCtD
Fluoxetine—Gastrointestinal disorder—Docetaxel—lung cancer	3.16e-05	0.000176	CcSEcCtD
Fluoxetine—Asthenia—Etoposide—lung cancer	3.16e-05	0.000176	CcSEcCtD
Fluoxetine—Fatigue—Docetaxel—lung cancer	3.16e-05	0.000176	CcSEcCtD
Fluoxetine—Nausea—Irinotecan—lung cancer	3.15e-05	0.000175	CcSEcCtD
Fluoxetine—Pain—Docetaxel—lung cancer	3.13e-05	0.000175	CcSEcCtD
Fluoxetine—Constipation—Docetaxel—lung cancer	3.13e-05	0.000175	CcSEcCtD
Fluoxetine—Back pain—Methotrexate—lung cancer	3.13e-05	0.000174	CcSEcCtD
Fluoxetine—Pruritus—Etoposide—lung cancer	3.12e-05	0.000174	CcSEcCtD
Fluoxetine—Visual impairment—Doxorubicin—lung cancer	3.1e-05	0.000173	CcSEcCtD
Fluoxetine—Asthenia—Paclitaxel—lung cancer	3.1e-05	0.000173	CcSEcCtD
Fluoxetine—Nausea—Gemcitabine—lung cancer	3.06e-05	0.000171	CcSEcCtD
Fluoxetine—Vomiting—Cisplatin—lung cancer	3.06e-05	0.00017	CcSEcCtD
Fluoxetine—Pruritus—Paclitaxel—lung cancer	3.06e-05	0.00017	CcSEcCtD
Fluoxetine—Erythema multiforme—Doxorubicin—lung cancer	3.04e-05	0.00017	CcSEcCtD
Fluoxetine—Rash—Cisplatin—lung cancer	3.03e-05	0.000169	CcSEcCtD
Fluoxetine—Dermatitis—Cisplatin—lung cancer	3.03e-05	0.000169	CcSEcCtD
Fluoxetine—Feeling abnormal—Docetaxel—lung cancer	3.02e-05	0.000168	CcSEcCtD
Fluoxetine—Diarrhoea—Etoposide—lung cancer	3.01e-05	0.000168	CcSEcCtD
Fluoxetine—Ill-defined disorder—Methotrexate—lung cancer	3e-05	0.000167	CcSEcCtD
Fluoxetine—Tinnitus—Doxorubicin—lung cancer	3e-05	0.000167	CcSEcCtD
Fluoxetine—Gastrointestinal pain—Docetaxel—lung cancer	2.99e-05	0.000167	CcSEcCtD
Fluoxetine—Anaemia—Methotrexate—lung cancer	2.99e-05	0.000167	CcSEcCtD
Fluoxetine—Diarrhoea—Paclitaxel—lung cancer	2.95e-05	0.000165	CcSEcCtD
Fluoxetine—Malaise—Methotrexate—lung cancer	2.92e-05	0.000163	CcSEcCtD
Fluoxetine—Dizziness—Etoposide—lung cancer	2.91e-05	0.000162	CcSEcCtD
Fluoxetine—Vertigo—Methotrexate—lung cancer	2.9e-05	0.000162	CcSEcCtD
Fluoxetine—Abdominal pain—Docetaxel—lung cancer	2.89e-05	0.000161	CcSEcCtD
Fluoxetine—Body temperature increased—Docetaxel—lung cancer	2.89e-05	0.000161	CcSEcCtD
Fluoxetine—Leukopenia—Methotrexate—lung cancer	2.89e-05	0.000161	CcSEcCtD
Fluoxetine—Chills—Doxorubicin—lung cancer	2.89e-05	0.000161	CcSEcCtD
Fluoxetine—Arrhythmia—Doxorubicin—lung cancer	2.87e-05	0.00016	CcSEcCtD
Fluoxetine—Dizziness—Paclitaxel—lung cancer	2.86e-05	0.000159	CcSEcCtD
Fluoxetine—Nausea—Cisplatin—lung cancer	2.86e-05	0.000159	CcSEcCtD
Fluoxetine—Alopecia—Doxorubicin—lung cancer	2.84e-05	0.000158	CcSEcCtD
Fluoxetine—Cough—Methotrexate—lung cancer	2.82e-05	0.000157	CcSEcCtD
Fluoxetine—Mental disorder—Doxorubicin—lung cancer	2.82e-05	0.000157	CcSEcCtD
Fluoxetine—Convulsion—Methotrexate—lung cancer	2.8e-05	0.000156	CcSEcCtD
Fluoxetine—Vomiting—Etoposide—lung cancer	2.8e-05	0.000156	CcSEcCtD
Fluoxetine—Malnutrition—Doxorubicin—lung cancer	2.8e-05	0.000156	CcSEcCtD
Fluoxetine—Rash—Etoposide—lung cancer	2.78e-05	0.000155	CcSEcCtD
Fluoxetine—Dermatitis—Etoposide—lung cancer	2.77e-05	0.000155	CcSEcCtD
Fluoxetine—Headache—Etoposide—lung cancer	2.76e-05	0.000154	CcSEcCtD
Fluoxetine—Flatulence—Doxorubicin—lung cancer	2.76e-05	0.000154	CcSEcCtD
Fluoxetine—Chest pain—Methotrexate—lung cancer	2.75e-05	0.000153	CcSEcCtD
Fluoxetine—Arthralgia—Methotrexate—lung cancer	2.75e-05	0.000153	CcSEcCtD
Fluoxetine—Myalgia—Methotrexate—lung cancer	2.75e-05	0.000153	CcSEcCtD
Fluoxetine—Tension—Doxorubicin—lung cancer	2.75e-05	0.000153	CcSEcCtD
Fluoxetine—Vomiting—Paclitaxel—lung cancer	2.75e-05	0.000153	CcSEcCtD
Fluoxetine—Dysgeusia—Doxorubicin—lung cancer	2.74e-05	0.000153	CcSEcCtD
Fluoxetine—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—lung cancer	2.73e-05	0.000152	CcSEcCtD
Fluoxetine—Rash—Paclitaxel—lung cancer	2.72e-05	0.000152	CcSEcCtD
Fluoxetine—Dermatitis—Paclitaxel—lung cancer	2.72e-05	0.000152	CcSEcCtD
Fluoxetine—Discomfort—Methotrexate—lung cancer	2.72e-05	0.000152	CcSEcCtD
Fluoxetine—Nervousness—Doxorubicin—lung cancer	2.72e-05	0.000152	CcSEcCtD
Fluoxetine—Back pain—Doxorubicin—lung cancer	2.71e-05	0.000151	CcSEcCtD
Fluoxetine—Headache—Paclitaxel—lung cancer	2.71e-05	0.000151	CcSEcCtD
Fluoxetine—Hypersensitivity—Docetaxel—lung cancer	2.7e-05	0.00015	CcSEcCtD
Fluoxetine—Muscle spasms—Doxorubicin—lung cancer	2.69e-05	0.00015	CcSEcCtD
Fluoxetine—Confusional state—Methotrexate—lung cancer	2.66e-05	0.000148	CcSEcCtD
Fluoxetine—Anaphylactic shock—Methotrexate—lung cancer	2.64e-05	0.000147	CcSEcCtD
Fluoxetine—Asthenia—Docetaxel—lung cancer	2.63e-05	0.000146	CcSEcCtD
Fluoxetine—Infection—Methotrexate—lung cancer	2.62e-05	0.000146	CcSEcCtD
Fluoxetine—Nausea—Etoposide—lung cancer	2.62e-05	0.000146	CcSEcCtD
Fluoxetine—Ill-defined disorder—Doxorubicin—lung cancer	2.6e-05	0.000145	CcSEcCtD
Fluoxetine—Pruritus—Docetaxel—lung cancer	2.59e-05	0.000144	CcSEcCtD
Fluoxetine—Anaemia—Doxorubicin—lung cancer	2.59e-05	0.000144	CcSEcCtD
Fluoxetine—Thrombocytopenia—Methotrexate—lung cancer	2.58e-05	0.000144	CcSEcCtD
Fluoxetine—Agitation—Doxorubicin—lung cancer	2.57e-05	0.000143	CcSEcCtD
Fluoxetine—Nausea—Paclitaxel—lung cancer	2.57e-05	0.000143	CcSEcCtD
Fluoxetine—Skin disorder—Methotrexate—lung cancer	2.56e-05	0.000143	CcSEcCtD
Fluoxetine—Hyperhidrosis—Methotrexate—lung cancer	2.55e-05	0.000142	CcSEcCtD
Fluoxetine—Malaise—Doxorubicin—lung cancer	2.52e-05	0.000141	CcSEcCtD
Fluoxetine—Vertigo—Doxorubicin—lung cancer	2.51e-05	0.00014	CcSEcCtD
Fluoxetine—Anorexia—Methotrexate—lung cancer	2.51e-05	0.00014	CcSEcCtD
Fluoxetine—Syncope—Doxorubicin—lung cancer	2.51e-05	0.00014	CcSEcCtD
Fluoxetine—Leukopenia—Doxorubicin—lung cancer	2.51e-05	0.00014	CcSEcCtD
Fluoxetine—Diarrhoea—Docetaxel—lung cancer	2.5e-05	0.00014	CcSEcCtD
Fluoxetine—Palpitations—Doxorubicin—lung cancer	2.47e-05	0.000138	CcSEcCtD
Fluoxetine—Hypotension—Methotrexate—lung cancer	2.47e-05	0.000137	CcSEcCtD
Fluoxetine—Loss of consciousness—Doxorubicin—lung cancer	2.46e-05	0.000137	CcSEcCtD
Fluoxetine—Cough—Doxorubicin—lung cancer	2.44e-05	0.000136	CcSEcCtD
Fluoxetine—Convulsion—Doxorubicin—lung cancer	2.43e-05	0.000135	CcSEcCtD
Fluoxetine—Dizziness—Docetaxel—lung cancer	2.42e-05	0.000135	CcSEcCtD
Fluoxetine—Hypertension—Doxorubicin—lung cancer	2.42e-05	0.000135	CcSEcCtD
Fluoxetine—Musculoskeletal discomfort—Methotrexate—lung cancer	2.4e-05	0.000134	CcSEcCtD
Fluoxetine—Insomnia—Methotrexate—lung cancer	2.39e-05	0.000133	CcSEcCtD
Fluoxetine—Myalgia—Doxorubicin—lung cancer	2.38e-05	0.000133	CcSEcCtD
Fluoxetine—Chest pain—Doxorubicin—lung cancer	2.38e-05	0.000133	CcSEcCtD
Fluoxetine—Arthralgia—Doxorubicin—lung cancer	2.38e-05	0.000133	CcSEcCtD
Fluoxetine—Anxiety—Doxorubicin—lung cancer	2.37e-05	0.000132	CcSEcCtD
Fluoxetine—Paraesthesia—Methotrexate—lung cancer	2.37e-05	0.000132	CcSEcCtD
Fluoxetine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—lung cancer	2.37e-05	0.000132	CcSEcCtD
Fluoxetine—Discomfort—Doxorubicin—lung cancer	2.35e-05	0.000131	CcSEcCtD
Fluoxetine—Dyspnoea—Methotrexate—lung cancer	2.35e-05	0.000131	CcSEcCtD
Fluoxetine—Somnolence—Methotrexate—lung cancer	2.35e-05	0.000131	CcSEcCtD
Fluoxetine—Dry mouth—Doxorubicin—lung cancer	2.33e-05	0.00013	CcSEcCtD
Fluoxetine—Vomiting—Docetaxel—lung cancer	2.33e-05	0.00013	CcSEcCtD
Fluoxetine—Dyspepsia—Methotrexate—lung cancer	2.32e-05	0.000129	CcSEcCtD
Fluoxetine—Rash—Docetaxel—lung cancer	2.31e-05	0.000129	CcSEcCtD
Fluoxetine—Dermatitis—Docetaxel—lung cancer	2.31e-05	0.000129	CcSEcCtD
Fluoxetine—Confusional state—Doxorubicin—lung cancer	2.3e-05	0.000128	CcSEcCtD
Fluoxetine—Decreased appetite—Methotrexate—lung cancer	2.29e-05	0.000128	CcSEcCtD
Fluoxetine—Headache—Docetaxel—lung cancer	2.29e-05	0.000128	CcSEcCtD
Fluoxetine—Anaphylactic shock—Doxorubicin—lung cancer	2.28e-05	0.000127	CcSEcCtD
Fluoxetine—Gastrointestinal disorder—Methotrexate—lung cancer	2.28e-05	0.000127	CcSEcCtD
Fluoxetine—Fatigue—Methotrexate—lung cancer	2.27e-05	0.000127	CcSEcCtD
Fluoxetine—Infection—Doxorubicin—lung cancer	2.27e-05	0.000127	CcSEcCtD
Fluoxetine—Pain—Methotrexate—lung cancer	2.26e-05	0.000126	CcSEcCtD
Fluoxetine—Shock—Doxorubicin—lung cancer	2.25e-05	0.000125	CcSEcCtD
Fluoxetine—Thrombocytopenia—Doxorubicin—lung cancer	2.24e-05	0.000125	CcSEcCtD
Fluoxetine—Tachycardia—Doxorubicin—lung cancer	2.23e-05	0.000124	CcSEcCtD
Fluoxetine—Skin disorder—Doxorubicin—lung cancer	2.22e-05	0.000124	CcSEcCtD
Fluoxetine—Hyperhidrosis—Doxorubicin—lung cancer	2.21e-05	0.000123	CcSEcCtD
Fluoxetine—Anorexia—Doxorubicin—lung cancer	2.18e-05	0.000121	CcSEcCtD
Fluoxetine—Nausea—Docetaxel—lung cancer	2.17e-05	0.000121	CcSEcCtD
Fluoxetine—Feeling abnormal—Methotrexate—lung cancer	2.17e-05	0.000121	CcSEcCtD
Fluoxetine—Gastrointestinal pain—Methotrexate—lung cancer	2.16e-05	0.00012	CcSEcCtD
Fluoxetine—Hypotension—Doxorubicin—lung cancer	2.13e-05	0.000119	CcSEcCtD
Fluoxetine—Urticaria—Methotrexate—lung cancer	2.1e-05	0.000117	CcSEcCtD
Fluoxetine—Body temperature increased—Methotrexate—lung cancer	2.09e-05	0.000116	CcSEcCtD
Fluoxetine—Abdominal pain—Methotrexate—lung cancer	2.09e-05	0.000116	CcSEcCtD
Fluoxetine—Musculoskeletal discomfort—Doxorubicin—lung cancer	2.08e-05	0.000116	CcSEcCtD
Fluoxetine—Insomnia—Doxorubicin—lung cancer	2.07e-05	0.000115	CcSEcCtD
Fluoxetine—Paraesthesia—Doxorubicin—lung cancer	2.05e-05	0.000114	CcSEcCtD
Fluoxetine—Dyspnoea—Doxorubicin—lung cancer	2.04e-05	0.000114	CcSEcCtD
Fluoxetine—Somnolence—Doxorubicin—lung cancer	2.03e-05	0.000113	CcSEcCtD
Fluoxetine—Dyspepsia—Doxorubicin—lung cancer	2.01e-05	0.000112	CcSEcCtD
Fluoxetine—Decreased appetite—Doxorubicin—lung cancer	1.99e-05	0.000111	CcSEcCtD
Fluoxetine—Gastrointestinal disorder—Doxorubicin—lung cancer	1.97e-05	0.00011	CcSEcCtD
Fluoxetine—Fatigue—Doxorubicin—lung cancer	1.97e-05	0.00011	CcSEcCtD
Fluoxetine—Constipation—Doxorubicin—lung cancer	1.95e-05	0.000109	CcSEcCtD
Fluoxetine—Pain—Doxorubicin—lung cancer	1.95e-05	0.000109	CcSEcCtD
Fluoxetine—Hypersensitivity—Methotrexate—lung cancer	1.94e-05	0.000108	CcSEcCtD
Fluoxetine—Asthenia—Methotrexate—lung cancer	1.89e-05	0.000106	CcSEcCtD
Fluoxetine—Feeling abnormal—Doxorubicin—lung cancer	1.88e-05	0.000105	CcSEcCtD
Fluoxetine—Gastrointestinal pain—Doxorubicin—lung cancer	1.87e-05	0.000104	CcSEcCtD
Fluoxetine—Pruritus—Methotrexate—lung cancer	1.87e-05	0.000104	CcSEcCtD
Fluoxetine—Urticaria—Doxorubicin—lung cancer	1.81e-05	0.000101	CcSEcCtD
Fluoxetine—Abdominal pain—Doxorubicin—lung cancer	1.81e-05	0.000101	CcSEcCtD
Fluoxetine—Body temperature increased—Doxorubicin—lung cancer	1.81e-05	0.000101	CcSEcCtD
Fluoxetine—Diarrhoea—Methotrexate—lung cancer	1.81e-05	0.000101	CcSEcCtD
Fluoxetine—Dizziness—Methotrexate—lung cancer	1.74e-05	9.73e-05	CcSEcCtD
Fluoxetine—Hypersensitivity—Doxorubicin—lung cancer	1.68e-05	9.38e-05	CcSEcCtD
Fluoxetine—Vomiting—Methotrexate—lung cancer	1.68e-05	9.35e-05	CcSEcCtD
Fluoxetine—Rash—Methotrexate—lung cancer	1.66e-05	9.27e-05	CcSEcCtD
Fluoxetine—Dermatitis—Methotrexate—lung cancer	1.66e-05	9.27e-05	CcSEcCtD
Fluoxetine—Headache—Methotrexate—lung cancer	1.65e-05	9.21e-05	CcSEcCtD
Fluoxetine—Asthenia—Doxorubicin—lung cancer	1.64e-05	9.14e-05	CcSEcCtD
Fluoxetine—Pruritus—Doxorubicin—lung cancer	1.62e-05	9.01e-05	CcSEcCtD
Fluoxetine—Nausea—Methotrexate—lung cancer	1.57e-05	8.74e-05	CcSEcCtD
Fluoxetine—Diarrhoea—Doxorubicin—lung cancer	1.56e-05	8.71e-05	CcSEcCtD
Fluoxetine—Dizziness—Doxorubicin—lung cancer	1.51e-05	8.42e-05	CcSEcCtD
Fluoxetine—Vomiting—Doxorubicin—lung cancer	1.45e-05	8.1e-05	CcSEcCtD
Fluoxetine—Rash—Doxorubicin—lung cancer	1.44e-05	8.03e-05	CcSEcCtD
Fluoxetine—Dermatitis—Doxorubicin—lung cancer	1.44e-05	8.02e-05	CcSEcCtD
Fluoxetine—Headache—Doxorubicin—lung cancer	1.43e-05	7.98e-05	CcSEcCtD
Fluoxetine—Nausea—Doxorubicin—lung cancer	1.36e-05	7.57e-05	CcSEcCtD
Fluoxetine—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—lung cancer	3.82e-06	5.03e-05	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—GSTP1—lung cancer	3.8e-06	5e-05	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism—GSTM1—lung cancer	3.79e-06	4.99e-05	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CB—lung cancer	3.78e-06	4.97e-05	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—ABCG2—lung cancer	3.76e-06	4.96e-05	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—ADCY1—lung cancer	3.76e-06	4.96e-05	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—GSTP1—lung cancer	3.76e-06	4.95e-05	CbGpPWpGaD
Fluoxetine—ABCB1—Metabolism—TYMS—lung cancer	3.74e-06	4.93e-05	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—lung cancer	3.74e-06	4.92e-05	CbGpPWpGaD
Fluoxetine—CYP2B6—Metabolism—PIK3CG—lung cancer	3.73e-06	4.91e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—MAP2K1—lung cancer	3.72e-06	4.9e-05	CbGpPWpGaD
Fluoxetine—ABCB1—Metabolism—GSTM1—lung cancer	3.7e-06	4.87e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—PIK3CD—lung cancer	3.7e-06	4.87e-05	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—CAT—lung cancer	3.69e-06	4.86e-05	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—HPGDS—lung cancer	3.69e-06	4.86e-05	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—ENO2—lung cancer	3.69e-06	4.86e-05	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—PPP2R1B—lung cancer	3.67e-06	4.83e-05	CbGpPWpGaD
Fluoxetine—HTR2C—GPCR downstream signaling—PIK3CA—lung cancer	3.66e-06	4.82e-05	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—CAT—lung cancer	3.66e-06	4.82e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—PIK3CG—lung cancer	3.65e-06	4.81e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—APC—lung cancer	3.65e-06	4.81e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—KIT—lung cancer	3.65e-06	4.81e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling by GPCR—NRAS—lung cancer	3.65e-06	4.81e-05	CbGpPWpGaD
Fluoxetine—CYP3A5—Metabolism—PIK3CG—lung cancer	3.64e-06	4.79e-05	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism of lipids and lipoproteins—EP300—lung cancer	3.64e-06	4.79e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling by GPCR—KRAS—lung cancer	3.62e-06	4.77e-05	CbGpPWpGaD
Fluoxetine—ALB—Hemostasis—PIK3CA—lung cancer	3.61e-06	4.76e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—EGF—lung cancer	3.61e-06	4.75e-05	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism—CYP1A1—lung cancer	3.6e-06	4.73e-05	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—ABCB1—lung cancer	3.59e-06	4.73e-05	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—GSTT1—lung cancer	3.58e-06	4.71e-05	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism—ERCC2—lung cancer	3.57e-06	4.69e-05	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—ABCB1—lung cancer	3.56e-06	4.69e-05	CbGpPWpGaD
Fluoxetine—CYP2B6—Metabolism—POMC—lung cancer	3.55e-06	4.67e-05	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—CYP2A6—lung cancer	3.54e-06	4.66e-05	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—GCLC—lung cancer	3.54e-06	4.66e-05	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—TYMS—lung cancer	3.53e-06	4.65e-05	CbGpPWpGaD
Fluoxetine—ABCB1—Metabolism—CYP1A1—lung cancer	3.51e-06	4.62e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling by GPCR—MAPK3—lung cancer	3.5e-06	4.61e-05	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—TYMS—lung cancer	3.5e-06	4.61e-05	CbGpPWpGaD
Fluoxetine—ALB—Hemostasis—TP53—lung cancer	3.5e-06	4.6e-05	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—GSTM1—lung cancer	3.49e-06	4.59e-05	CbGpPWpGaD
Fluoxetine—ABCB1—Metabolism—ERCC2—lung cancer	3.48e-06	4.58e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—POMC—lung cancer	3.48e-06	4.58e-05	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—STK11—lung cancer	3.48e-06	4.57e-05	CbGpPWpGaD
Fluoxetine—CYP3A5—Metabolism—POMC—lung cancer	3.47e-06	4.56e-05	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—GSTM1—lung cancer	3.46e-06	4.55e-05	CbGpPWpGaD
Fluoxetine—CYP2B6—Metabolism—CREBBP—lung cancer	3.45e-06	4.55e-05	CbGpPWpGaD
Fluoxetine—ALB—Metabolism—APOA1—lung cancer	3.44e-06	4.52e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—BRAF—lung cancer	3.43e-06	4.52e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—IL6R—lung cancer	3.39e-06	4.47e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—CREBBP—lung cancer	3.39e-06	4.46e-05	CbGpPWpGaD
Fluoxetine—CYP3A5—Metabolism—CREBBP—lung cancer	3.38e-06	4.45e-05	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—ENO1—lung cancer	3.35e-06	4.42e-05	CbGpPWpGaD
Fluoxetine—ALB—Hemostasis—HRAS—lung cancer	3.34e-06	4.4e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling by GPCR—EGFR—lung cancer	3.33e-06	4.38e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling by GPCR—PIK3CA—lung cancer	3.33e-06	4.38e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—MDM2—lung cancer	3.31e-06	4.36e-05	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—CYP1A1—lung cancer	3.31e-06	4.35e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—RAF1—lung cancer	3.3e-06	4.35e-05	CbGpPWpGaD
Fluoxetine—ALB—Metabolism of lipids and lipoproteins—PIK3CA—lung cancer	3.29e-06	4.33e-05	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—ERCC2—lung cancer	3.28e-06	4.32e-05	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—CYP1A1—lung cancer	3.28e-06	4.32e-05	CbGpPWpGaD
Fluoxetine—CYP2B6—Metabolism—PIK3CD—lung cancer	3.28e-06	4.31e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—ERBB2—lung cancer	3.27e-06	4.3e-05	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—lung cancer	3.26e-06	4.29e-05	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—ERCC2—lung cancer	3.25e-06	4.28e-05	CbGpPWpGaD
Fluoxetine—CYP2B6—Metabolism—ALB—lung cancer	3.23e-06	4.26e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—MAP2K1—lung cancer	3.23e-06	4.26e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—MTOR—lung cancer	3.22e-06	4.24e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—PIK3CB—lung cancer	3.22e-06	4.24e-05	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—GSTP1—lung cancer	3.22e-06	4.23e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—PIK3CD—lung cancer	3.21e-06	4.23e-05	CbGpPWpGaD
Fluoxetine—CYP3A5—Metabolism—PIK3CD—lung cancer	3.2e-06	4.22e-05	CbGpPWpGaD
Fluoxetine—HTR2A—GPCR downstream signaling—PIK3CA—lung cancer	3.18e-06	4.19e-05	CbGpPWpGaD
Fluoxetine—CYP3A5—Metabolism—ALB—lung cancer	3.16e-06	4.16e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling by GPCR—KRAS—lung cancer	3.14e-06	4.14e-05	CbGpPWpGaD
Fluoxetine—ALB—Metabolism—PIK3CG—lung cancer	3.14e-06	4.13e-05	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—CAT—lung cancer	3.13e-06	4.12e-05	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism of lipids and lipoproteins—EP300—lung cancer	3.11e-06	4.1e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—CXCL8—lung cancer	3.1e-06	4.08e-05	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism—APOA1—lung cancer	3.08e-06	4.06e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling by GPCR—HRAS—lung cancer	3.08e-06	4.05e-05	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—ABCB1—lung cancer	3.04e-06	4.01e-05	CbGpPWpGaD
Fluoxetine—ABCB1—Metabolism—APOA1—lung cancer	3.01e-06	3.96e-05	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—CYP2E1—lung cancer	3.01e-06	3.96e-05	CbGpPWpGaD
Fluoxetine—HTR2C—GPCR downstream signaling—AKT1—lung cancer	2.99e-06	3.94e-05	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—TYMS—lung cancer	2.99e-06	3.94e-05	CbGpPWpGaD
Fluoxetine—ALB—Metabolism—POMC—lung cancer	2.99e-06	3.93e-05	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—NQO1—lung cancer	2.98e-06	3.92e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—CASP3—lung cancer	2.96e-06	3.9e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—IL2—lung cancer	2.96e-06	3.9e-05	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—GSTM1—lung cancer	2.95e-06	3.89e-05	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—lung cancer	2.95e-06	3.89e-05	CbGpPWpGaD
Fluoxetine—ALB—Hemostasis—AKT1—lung cancer	2.95e-06	3.89e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling by GPCR—IL6—lung cancer	2.95e-06	3.88e-05	CbGpPWpGaD
Fluoxetine—ALB—Metabolism—CREBBP—lung cancer	2.91e-06	3.83e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling by GPCR—PIK3CA—lung cancer	2.89e-06	3.8e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—CCND1—lung cancer	2.89e-06	3.8e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—JUN—lung cancer	2.88e-06	3.79e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—MDM2—lung cancer	2.88e-06	3.79e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—RAF1—lung cancer	2.87e-06	3.77e-05	CbGpPWpGaD
Fluoxetine—CYP2B6—Metabolism—PIK3CB—lung cancer	2.86e-06	3.76e-05	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—APOA1—lung cancer	2.84e-06	3.73e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—ERBB2—lung cancer	2.84e-06	3.73e-05	CbGpPWpGaD
Fluoxetine—CYP2B6—Metabolism—PTGS2—lung cancer	2.83e-06	3.72e-05	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism—PIK3CG—lung cancer	2.82e-06	3.71e-05	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—APOA1—lung cancer	2.81e-06	3.7e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—MMP9—lung cancer	2.8e-06	3.69e-05	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—CYP1A1—lung cancer	2.8e-06	3.69e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—PIK3CB—lung cancer	2.8e-06	3.69e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—MTOR—lung cancer	2.8e-06	3.69e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—CDKN1A—lung cancer	2.79e-06	3.68e-05	CbGpPWpGaD
Fluoxetine—CYP3A5—Metabolism—PIK3CB—lung cancer	2.79e-06	3.67e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—PTEN—lung cancer	2.79e-06	3.67e-05	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—ERCC2—lung cancer	2.78e-06	3.66e-05	CbGpPWpGaD
Fluoxetine—CYP3A5—Metabolism—PTGS2—lung cancer	2.77e-06	3.64e-05	CbGpPWpGaD
Fluoxetine—ALB—Metabolism—PIK3CD—lung cancer	2.76e-06	3.63e-05	CbGpPWpGaD
Fluoxetine—ABCB1—Metabolism—PIK3CG—lung cancer	2.75e-06	3.62e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling by GPCR—AKT1—lung cancer	2.72e-06	3.58e-05	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—lung cancer	2.69e-06	3.55e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—CXCL8—lung cancer	2.69e-06	3.54e-05	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—STK11—lung cancer	2.68e-06	3.53e-05	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism—POMC—lung cancer	2.68e-06	3.53e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling by GPCR—HRAS—lung cancer	2.67e-06	3.52e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—EP300—lung cancer	2.66e-06	3.5e-05	CbGpPWpGaD
Fluoxetine—ABCB1—Metabolism—POMC—lung cancer	2.62e-06	3.44e-05	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism—CREBBP—lung cancer	2.61e-06	3.44e-05	CbGpPWpGaD
Fluoxetine—HTR2A—GPCR downstream signaling—AKT1—lung cancer	2.6e-06	3.42e-05	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—PIK3CG—lung cancer	2.59e-06	3.41e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—SRC—lung cancer	2.58e-06	3.4e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—CASP3—lung cancer	2.57e-06	3.39e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—IL2—lung cancer	2.57e-06	3.38e-05	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—PIK3CG—lung cancer	2.57e-06	3.38e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling by GPCR—IL6—lung cancer	2.56e-06	3.37e-05	CbGpPWpGaD
Fluoxetine—ABCB1—Metabolism—CREBBP—lung cancer	2.55e-06	3.35e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—VEGFA—lung cancer	2.52e-06	3.31e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—CCND1—lung cancer	2.51e-06	3.3e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—JUN—lung cancer	2.5e-06	3.29e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—STAT3—lung cancer	2.49e-06	3.28e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—NRAS—lung cancer	2.49e-06	3.27e-05	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—GSTP1—lung cancer	2.48e-06	3.27e-05	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism—PIK3CD—lung cancer	2.48e-06	3.26e-05	CbGpPWpGaD
Fluoxetine—CYP2B6—Metabolism—PTEN—lung cancer	2.47e-06	3.25e-05	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—POMC—lung cancer	2.47e-06	3.25e-05	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—POMC—lung cancer	2.44e-06	3.22e-05	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism—ALB—lung cancer	2.44e-06	3.22e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—MMP9—lung cancer	2.43e-06	3.2e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—CDKN1A—lung cancer	2.42e-06	3.19e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—PTEN—lung cancer	2.42e-06	3.18e-05	CbGpPWpGaD
Fluoxetine—ABCB1—Metabolism—PIK3CD—lung cancer	2.42e-06	3.18e-05	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—CAT—lung cancer	2.41e-06	3.18e-05	CbGpPWpGaD
Fluoxetine—CYP3A5—Metabolism—PTEN—lung cancer	2.41e-06	3.17e-05	CbGpPWpGaD
Fluoxetine—ALB—Metabolism—PIK3CB—lung cancer	2.4e-06	3.16e-05	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—APOA1—lung cancer	2.4e-06	3.16e-05	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—CREBBP—lung cancer	2.4e-06	3.16e-05	CbGpPWpGaD
Fluoxetine—ABCB1—Metabolism—ALB—lung cancer	2.39e-06	3.14e-05	CbGpPWpGaD
Fluoxetine—ALB—Metabolism—PTGS2—lung cancer	2.38e-06	3.14e-05	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—CREBBP—lung cancer	2.38e-06	3.13e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—MAPK3—lung cancer	2.38e-06	3.13e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling by GPCR—AKT1—lung cancer	2.36e-06	3.11e-05	CbGpPWpGaD
Fluoxetine—CYP2B6—Metabolism—EP300—lung cancer	2.35e-06	3.1e-05	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—ABCB1—lung cancer	2.35e-06	3.09e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—MYC—lung cancer	2.31e-06	3.05e-05	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—TYMS—lung cancer	2.31e-06	3.04e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—EP300—lung cancer	2.31e-06	3.04e-05	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—lung cancer	2.3e-06	3.03e-05	CbGpPWpGaD
Fluoxetine—CYP3A5—Metabolism—EP300—lung cancer	2.3e-06	3.03e-05	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—GSTM1—lung cancer	2.28e-06	3e-05	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—PIK3CD—lung cancer	2.28e-06	3e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—EGFR—lung cancer	2.26e-06	2.98e-05	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—PIK3CD—lung cancer	2.26e-06	2.97e-05	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—ALB—lung cancer	2.25e-06	2.96e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—SRC—lung cancer	2.24e-06	2.95e-05	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—ALB—lung cancer	2.23e-06	2.93e-05	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—PIK3CG—lung cancer	2.19e-06	2.89e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—VEGFA—lung cancer	2.18e-06	2.88e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—STAT3—lung cancer	2.16e-06	2.85e-05	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—CYP1A1—lung cancer	2.16e-06	2.85e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—NRAS—lung cancer	2.16e-06	2.84e-05	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism—PIK3CB—lung cancer	2.16e-06	2.84e-05	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—ERCC2—lung cancer	2.14e-06	2.82e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—KRAS—lung cancer	2.14e-06	2.82e-05	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism—PTGS2—lung cancer	2.14e-06	2.81e-05	CbGpPWpGaD
Fluoxetine—ABCB1—Metabolism—PIK3CB—lung cancer	2.11e-06	2.77e-05	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—POMC—lung cancer	2.09e-06	2.75e-05	CbGpPWpGaD
Fluoxetine—ABCB1—Metabolism—PTGS2—lung cancer	2.09e-06	2.75e-05	CbGpPWpGaD
Fluoxetine—ALB—Metabolism—PTEN—lung cancer	2.08e-06	2.73e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—MAPK3—lung cancer	2.07e-06	2.72e-05	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—CREBBP—lung cancer	2.03e-06	2.68e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—MYC—lung cancer	2.01e-06	2.65e-05	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—PIK3CB—lung cancer	1.98e-06	2.61e-05	CbGpPWpGaD
Fluoxetine—ALB—Metabolism—EP300—lung cancer	1.98e-06	2.61e-05	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—PIK3CB—lung cancer	1.97e-06	2.59e-05	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—PTGS2—lung cancer	1.97e-06	2.59e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—EGFR—lung cancer	1.97e-06	2.59e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—PIK3CA—lung cancer	1.97e-06	2.59e-05	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—PTGS2—lung cancer	1.95e-06	2.57e-05	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—PIK3CD—lung cancer	1.93e-06	2.54e-05	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—ALB—lung cancer	1.9e-06	2.51e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—TP53—lung cancer	1.9e-06	2.5e-05	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism—PTEN—lung cancer	1.86e-06	2.45e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—KRAS—lung cancer	1.86e-06	2.45e-05	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—APOA1—lung cancer	1.85e-06	2.44e-05	CbGpPWpGaD
Fluoxetine—ABCB1—Metabolism—PTEN—lung cancer	1.82e-06	2.4e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—HRAS—lung cancer	1.82e-06	2.39e-05	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism—EP300—lung cancer	1.78e-06	2.34e-05	CbGpPWpGaD
Fluoxetine—CYP2B6—Metabolism—PIK3CA—lung cancer	1.74e-06	2.29e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—IL6—lung cancer	1.74e-06	2.29e-05	CbGpPWpGaD
Fluoxetine—ABCB1—Metabolism—EP300—lung cancer	1.74e-06	2.28e-05	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—PTEN—lung cancer	1.71e-06	2.26e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—PIK3CA—lung cancer	1.71e-06	2.25e-05	CbGpPWpGaD
Fluoxetine—CYP3A5—Metabolism—PIK3CA—lung cancer	1.7e-06	2.24e-05	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—PTEN—lung cancer	1.7e-06	2.24e-05	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—PIK3CG—lung cancer	1.69e-06	2.23e-05	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—PIK3CB—lung cancer	1.68e-06	2.21e-05	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—PTGS2—lung cancer	1.67e-06	2.19e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—TP53—lung cancer	1.65e-06	2.17e-05	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—EP300—lung cancer	1.64e-06	2.15e-05	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—EP300—lung cancer	1.62e-06	2.13e-05	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—POMC—lung cancer	1.61e-06	2.12e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—AKT1—lung cancer	1.61e-06	2.11e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—HRAS—lung cancer	1.58e-06	2.08e-05	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—CREBBP—lung cancer	1.57e-06	2.07e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—IL6—lung cancer	1.51e-06	1.99e-05	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—PIK3CD—lung cancer	1.49e-06	1.96e-05	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—ALB—lung cancer	1.47e-06	1.93e-05	CbGpPWpGaD
Fluoxetine—ALB—Metabolism—PIK3CA—lung cancer	1.47e-06	1.93e-05	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—PTEN—lung cancer	1.45e-06	1.91e-05	CbGpPWpGaD
Fluoxetine—CYP2B6—Metabolism—AKT1—lung cancer	1.42e-06	1.87e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—AKT1—lung cancer	1.39e-06	1.84e-05	CbGpPWpGaD
Fluoxetine—CYP3A5—Metabolism—AKT1—lung cancer	1.39e-06	1.83e-05	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—EP300—lung cancer	1.39e-06	1.82e-05	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism—PIK3CA—lung cancer	1.32e-06	1.73e-05	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—PIK3CB—lung cancer	1.3e-06	1.71e-05	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—PTGS2—lung cancer	1.29e-06	1.69e-05	CbGpPWpGaD
Fluoxetine—ABCB1—Metabolism—PIK3CA—lung cancer	1.28e-06	1.69e-05	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—PIK3CA—lung cancer	1.21e-06	1.59e-05	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—PIK3CA—lung cancer	1.2e-06	1.58e-05	CbGpPWpGaD
Fluoxetine—ALB—Metabolism—AKT1—lung cancer	1.2e-06	1.58e-05	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—PTEN—lung cancer	1.12e-06	1.48e-05	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism—AKT1—lung cancer	1.07e-06	1.41e-05	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—EP300—lung cancer	1.07e-06	1.41e-05	CbGpPWpGaD
Fluoxetine—ABCB1—Metabolism—AKT1—lung cancer	1.05e-06	1.38e-05	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—PIK3CA—lung cancer	1.02e-06	1.35e-05	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—AKT1—lung cancer	9.88e-07	1.3e-05	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—AKT1—lung cancer	9.8e-07	1.29e-05	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—AKT1—lung cancer	8.37e-07	1.1e-05	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—PIK3CA—lung cancer	7.91e-07	1.04e-05	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—AKT1—lung cancer	6.46e-07	8.51e-06	CbGpPWpGaD
